[Our experience with mitomycin C in the prophylaxis of superficial bladder tumors; retrospective study].
From 1984 to 1991, fifty-one patients completed prophylactic endovesical treatment with mitomycin C after transurethral resection of a bladder carcinoma Ta, Tl. The mean disease-free period was 31.2 months; twenty patients had recurrences (39.2%) and five (9.8%) had a progression in tumor stage. No statistically significant differences were found relative to the recurrences and tumor number, stage and size. The patients with prior tumors had recurrences before (p < 0.05) and more times (p < 0.01) than the primary group.
Moyano Calvo
J L
JL
Servicio de Urología, Hospital de la Princesa, Madrid, España.
Herrero Torres
L
L
Melón Rey
F J
FJ
Rabadán Ruiz
M
M
Pereira Sanz
I
I
D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000627:therapeutic use*; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology / Q000517:prevention & control*; D012189:Retrospective Studies; D001749:Urinary Bladder Neoplasms / Q000453:epidemiology / Q000517:prevention & control*
D016685:Mitomycin
Nuestra experiencia con mitomicin C como profilaxis en los tumores superficiales de vejiga; estudio retrospectivo.